1. Period circadian clock 3 is crucial for regulation of IL-22-producing type 3 innate lymphoid cells by flavonoids from Shen Ling Bai Zhu San to alleviate colitis.
- Author
-
Qu Q, Ma YM, Zhang WB, Chen R, Wang ZH, Jin WX, Huang YW, Xuan ZY, Liu MJ, Chen XL, Lv WJ, and Guo SN
- Subjects
- Animals, Mice, Male, Interleukin-22, Interleukins genetics, Interleukins metabolism, Colitis drug therapy, Colitis immunology, Colitis chemically induced, Colitis metabolism, Lymphocytes drug effects, Lymphocytes immunology, Lymphocytes metabolism, Drugs, Chinese Herbal pharmacology, Immunity, Innate drug effects, Flavonoids pharmacology
- Abstract
Type 3 Innate lymphoid cells (ILC3s) functions bear complex response during Inflammatory bowel diseases (IBD). Here, our study first analyzed the main pharmacological components in Shen Ling Bai Zhu San n-butanol extracts (S-Nb), and then explored whether S-Nb administrated immune response of ILC3s, and how it regulates ILC3s. Shen Ling Bai Zhu San (SLBZS) or S-Nb were administrated for 7 days to analyze the frequency of ILC3s and their produced cytokine. Using siRNA technology to knock down the expression of period circadian clock 2 (Per2) and period circadian clock 3 (Per3) and Anti-IL-22 antibody was supplied to mice, then detecting the moderator effect of S-Nb on colitis. The most class of S-Nb is flavonoids, with a content of approximately 48%. Oral administration of S-Nb enhanced the production of NCR
+ ILC3s and IL-22 produced by ILC3s, but did not alter IL-17A. Surprisingly, knocking down the expression of Per3 instead of Per2 inhibited the modulation effect of S-Nb on colitis and reduced IL-22 production, whether originating from NCR+ ILC3s or NCR- ILC3s. After neutralizing the expression of IL-22 in mice, S-Nb was deprived of ability to alleviate colitis. The reason why S-Nb alleviates colitis is by enhancing the expression of Per3 via flavonoids, which in turn promotes the secretion of IL-22+ ILC3s in intestine., Competing Interests: Declaration of competing interest All authors declare that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2025
- Full Text
- View/download PDF